Cancerous cells

 

CERVICAL CANCER FACTS

Approximately 528,000 women worldwide develop cervical cancer each year and it is the fourth leading cause of cancer death in women. Despite well-established cervical cancer screening programs, the incidence of invasive cervical cancer in the US has been increasing at a rate of 3% per year since 1986 (SEER Cancer Statistics Review). Thus, cervical cancer continues to be a major health care problem in the U.S. and worldwide.

See more

 


SCIENTIFIC INTEGRATION
Interactions and Collaborations

The Cervical Cancer SPORE is a highly interactive and multidisciplinary program incorporating five projects and three cores. Their interconnection is depicted in Chart 5. The relationships that exist among many of the participating investigators are already well established and have resulted in productive developments and opportunities, as demonstrated by joint authored research articles, cooperation on grants, and translational application of some research developments in clinical trials.

See more 

 

Plasmid DNA encoding HSP70 protein linked to a detoxified version of HPV-16 E7 antigen to enhance vaccine potency

Enlarge picture


CLINICAL TRANSLATION
SPORE Interactions and Collaborations

Our Cervical Cancer SPORE application incorporates translational research in 3 major program areas – Program 1: Preventive HPV Vaccines for Cervical Cancer (Project I), Program 2: Therapeutic HPV Vaccines to Control HPV-Associated Precursor Lesions (Project II, III, and IV), and Program 3: Therapeutic Vaccines to Control Invasive Cervical Cancer (Project V)

Program 1:
Project I: RG1-VLP as a Next Generation Preventive HPV Vaccine, led by Robert Garcea, M.D., Richard Roden, Ph.D., and Warner Huh, M.D. Project II: DNA Prime TA-CIN boost for Persistent HPV16+ ASC-US/LSIL, led by Richard Roden, Ph.D., and Warner Huh, M.D., and Chien-Fu Hung, Ph.D.

See more 

 

NCI SPOREs

SPOREs Overview
In 1992, the NCI established the Specialized Programs of Research Excellence (SPOREs) to promote interdisciplinary research and to speed the bi-directional exchange between basic and clinical science to move basic research finding from the laboratory to applied settings involving patients and populations.

 

The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, improve survival, and to improve the quality of life. Laboratory and clinical scientists work collaboratively to plan, design and implement research programs that impact on cancer prevention, detection, diagnosis, treatment and control.

See NCI's SPORE web site

 

 

 

ANNOUNCEMENT

Several pilot project and career enhancement grants are available to support new projects in advanced cervical cancer-related research. Priority will be given to translational research projects, as well as to projects related to the development of human immunological assays against the human papillomavirus. Basic research that has obvious, near-term potential application will also be considered. Funds for the pilot project and career enhancement program are provided by our NCI Cervical Cancer SPORE grant. The 2018-2019 application period has ended.

 

See the Guidelines for Submission

 

 


 

 

Copyright © 2004-2018 The Johns Hopkins University. All rights reserved.